The full name of the drug Margetuximab/Meganrol

Margetuximab appears under the generic name margetuximab-cmkb internationally and is an innovative monoclonal antibody drug targeting HER2-positive breast cancer. As a second-generation anti- HER2 monoclonal antibody, margetuximab has optimized the Fc fragment in its structural design to enhance the ability of immune effector cells to recognize tumors while retaining the specificity of targeting HER2. This structural improvement enables it to perform well in antibody-dependent cellular cytotoxicity (ADCC) and is expected to have better efficacy in some patients who have previously received trastuzumab but still have disease progression.

In clinical practice, magituximab is widely used in patients with metastatic or refractory HER2-positive breast cancer. Its mechanism of action is similar to trastuzumab, but optimization of the Fc fragment brings the potential for enhanced immune effects. The full drug name of margetuximab is not only reflected in the registration documents, but is also widely used in academic literature and clinical guidelines to ensure that professional medical personnel and scientific researchers can accurately identify the drug ingredients and indications.

The addition of the suffix cmkb to the full name reflects that it is a specifically engineered version of a monoclonal antibody. Compared with the original antibody, its molecular structure optimization part is to adjust the glycosylation pattern of the Fc fragment through artificial engineering technology to enhance the anti-tumor effect mediated by natural killer cells (NK cells). This design concept stems from an in-depth understanding of the drug resistance mechanism of HER2-positive breast cancer, especially that patients with different FcγR genotypes have significantly different responses to traditional anti-HER2 drugs, and margetuximab can improve the immune-mediated killing effect in some patients, thereby potentially improving efficacy.

International guidelines clearly state that magituximab belongs to a HER2-targeted therapy and should be used in combination with chemotherapy for patients with advanced or metastatic breast cancer who have received at least two HER2-targeted therapies in the past. Its full drug name and structural optimization background help doctors accurately select drugs and make individualized treatment decisions in overseas clinical practice.

Reference materials:https://www.margenza.com/